HEALTHWORLD HOSPITALS | PIONEER HEALTHCARE PLATFORM IN DURGAPUR

Global Swine Respiratory Diseases Treatment Market: SnapshotRespiratory disease in pigs has been a cause of substantial mortality and economic burden or the swine industry.

Particularly, according to a statistics, swine respiratory diseases involve multiple infectious agents, and have been one of the key causes of death in nursery pigs.

This has invigorated research on the aetiology of pneumonic swine’s lungs—the main agent being mycoplasma hyopneumoniae.Read Report Overview- https://www.transparencymarketresearch.com/swine-respiratory-diseases-treatment-market.htmlGrowing body of research pertaining to metagenomic analysis of murine respiratory tracts has helped in understanding the etiological agents of swine enzootic pneumonia and especially porcine respiratory disease complex.

They seem to increasingly focus on infectious diseases, and resultantly expand our understanding of primary respiratory infectious agents—virus as well as bacteria.One of the key pharmaceutical companies Boehringer Ingelheim showing interest in bringing effective control and treatment strategies for PRRSV to the market has sponsored three awards amounting to whopping $35,000.

Under the aegis of Awards for Advancing Research in Respiratory Disease, researchers and practicing veterinarians, the company announced, can now apply for any one of the these awards.Such initiatives no doubt promote the spirit of collaborations among researchers, thereby cementing prospects in the global swine respiratory diseases treatment market.

The primary pathogens under scanner are porcine reproductive and respiratory syndrome virus (PRRSV), swine influenza virus, and porcine circovirus type 2.

Increasing incidences of peripheral vascular diseases, liver cancer, strokes, and uterine fibroids coupled with rising preference for minimally invasive procedures; increasing investments, funds, and grants by public-private organizations for research; and technological advancements in the market will fuel the market growth over the forecast period.The embolotherapy devices market is projected to reach USD 4.9 billion by 2024 from USD 3.3 billion in 2019, at a CAGR of 8.1% from 2019 to 2024.The growth of the embolotherapy market is mainly attributed to factors such as the growth in the target patient population, rising preference for minimally invasive procedures, technological advancements in embolotherapy devices, and favorable reimbursement scenario.The embolic agents segment accounted for the largest share of the embolotherapy devices market, by product, in 2019Based on product, the embolotherapy market is segmented into embolic agents (embolic coils, embolic plug systems, liquid embolic agents, microspheres, and detachable balloons) and support devices (microcatheters and guidewires).

Microspheres accounted for the largest share of the embolotherapy market in 2018.

Market growth in this segment is attributed to the surge in the prevalence of hepatocellular carcinoma (microspheres are widely used to treat this disease), coupled with favorable reimbursement criteria in developed economies.Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=185897830The cancer segment is projected to hold the largest share of the market by disease indication during the forecast period of 2019 to 2024By disease indication, the embolotherapy market is classified into cancer, peripheral vascular diseases, neurological diseases, urological & nephrological disorders, and gastrointestinal disorders.

The cancer segment held the largest share of the embolotherapy market in 2019.

The rising preference for minimally invasive procedures, expansion of the target patient population, growing public-private funding & government support for cancer research, and technological advancements in the field of microspheres are driving the growth of this segment.Hospitals and clinics were the key end users in the embolotherapy devices marketOn the basis of end users, the embolotherapy market is segmented into hospitals and clinics, ambulatory surgery centers (ASCs), and other end users.

In 2018, the hospital and clinics segment held the largest share of the embolotherapy market.